Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer

deVos, Theo; Tetzner, Reimo; Model, Fabian; Weiß, Günter; Schuster, Matthias; Distler, Jürgen; Steiger, Kathryn V.; Grützmann, Robert; Pilarsky, Christian; Habermann, Jens K.; Fleshner, Phillip; Oubre, Benton M.; Day, Robert W.; Sledziewski, Andrew; Lofton–Day, Catherine

doi:10.1373/clinchem.2008.115808

Cited by 453 publications

(293 citation statements)

References 23 publications

(36 reference statements)

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…Likewise, septin 9 (SEPT9), is a hypermethylation biomarker for CRC. In a blinded study the SEPT9 plasma assay showed a sensitivity of 67% and specificity of 89% for detection of colorectal cancer (deVos et al 2009, Tanzer et al 2010. Based on preclinical data from such studies, the PRESEPT trial, a prospective, population-based study to determine the clinical performance of SEPT9 for colorectal cancer screening of guideline-eligible individuals, opened in 2009 and closed recently with publication of results anticipated in the near future.…”

Section: Dna Methylation Biomarkers For Cancer Detection and Tumor Prmentioning

confidence: 99%

A decade of DNA methylation profiling in cancer: What have we learned?

Sharma

Kuerbitz

2015

MRAJ

View full text Add to dashboard Cite

Abstract-Investigators have studied DNA methylation in tumor cells for nearly 50 years. Differences in gene-specific methylation between cancer cells and their normal counterparts were described more than 30 years ago. From early techniques that measured overall DNA methylation levels to enzyme-associated techniques that interrogated methylation at a single CpG dinucleotide to present day assays that catalogue the methylation of every cytosine in the genome, technical advancement progressively has brought increasing clarity to our understanding of the complex epigenomes of normal and neoplastic cells. Over the past 10 years we have been witness to an explosion of investigation into the epigenetic basis of cancer, and application of the powerful genome-wide DNA methylation profiling techniques to be reviewed have yielded critical insights into the organization of the cancer methylome with its broad regions of hypomethylation and foci of hypermethylation resulting in critical differences in gene expression and chromosomal stability compared to normal cells. These insights, in turn, have prompted novel, testable hypotheses, to be discussed, pertaining to fundamental aspects of cancer biology including the potential stem cell/progenitor cell origins of cancer and the plasticity of gene expression that may underlie tumor heterogeneity and tumor progression. Finally to be discussed is the growing portfolio of epigenetic tools being provided by modern methylome profiling analyses. These biomarker tools are complementing and extending the current genomic tests that are improving cancer diagnosis and that increasingly will facilitate highly individualized cancer treatment in the upcoming decade.

show abstract

Section: Dna Methylation Biomarkers For Cancer Detection and Tumor Prmentioning

confidence: 99%

A decade of DNA methylation profiling in cancer: What have we learned?

Sharma

Kuerbitz

2015

MRAJ

View full text Add to dashboard Cite

show abstract

“…Several septins have been identified as mixed lineage leukemia (MLL) fusion partners that contribute to the pathogenesis of leukemia (Borkhardt et al, 2001;Cerveira et al, 2006;Kojima et al, 2004;Osaka et al, 1999). Notably, septins are also being used in a diagnostic context, with the methylation of the SEPT9 promoter serving as an effective biomarker for colorectal cancer (deVos et al, 2009;Grutzmann et al, 2008;Lofton-Day et al, 2008). The role of septins in neurological disorders and cancer is complex and poorly understood.…”

Section: Septin-associated Diseasesmentioning

confidence: 99%

Septins at a glance

Beise

Trimble

2011

Journal of Cell Science

View full text Add to dashboard Cite

“…Most recently, serum metabolites have been studied to be used as potential biomarkers for early CRC detection [13]. Some important biomarkers characteristic of early CRC development such as methylated Septin 9 (SEPT9) and miRNA-21 have been reported [14,15]. These experimental screening techniques, though promising to provide potential markers for early CRC diagnosis, still require further validation in population-based studies [16].…”

Section: Introductionmentioning

confidence: 99%

Label-free surface-enhanced Raman spectroscopy for detection of colorectal cancer and precursor lesions using blood plasma

Feng

Wang

Tai

et al. 2015

Biomed. Opt. Express

View full text Add to dashboard Cite

Fecal based tests have limited diagnostic values in detecting adenomatous polyps, the precursor lesions to colorectal cancer (CRC). Surface enhanced Raman spectroscopy (SERS) using silver nanoparticles as substrate is a multiplexed analytical technique capable of detecting biomolecules with high sensitivity. This study utilizes SERS to analyze blood plasma for detecting both CRC and adenomatous polyps for the first time. Blood plasma samples are collected from healthy control subjects and patients diagnosed with adenomas and CRC. Using a real-time Raman system, SERS spectra for blood plasma samples are measured in 1 s. The collected SERS spectra are analyzed with partial least squares-discriminant analysis. Classification of normal versus CRC plus adenomatous polyps achieved diagnostic sensitivity of 86.4% and specificity of 80%. The results suggest that blood plasma SERS analysis could be a potential screening test to detect both CRC and adenomas. Gastroenterol. 19(12), 1855-1860 (2013). 7. F. Stracci, M. Zorzi, and G. Grazzini, "Colorectal cancer screening: tests, strategies, and perspectives," Front. ©2015 Optical Society of AmericaPublic Health 2, 210 (2014). 8. A. A. Plumb and S. Halligan, "Colorectal cancer screening," Semin. Roentgenol. 50(2), 101-110 (2015). #242906Received 16 #242906Received 16

show abstract

Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer

Cited by 453 publications

References 23 publications

A decade of DNA methylation profiling in cancer: What have we learned?

A decade of DNA methylation profiling in cancer: What have we learned?

Septins at a glance

Label-free surface-enhanced Raman spectroscopy for detection of colorectal cancer and precursor lesions using blood plasma

Contact Info

Product

Resources

About